<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204123</url>
  </required_header>
  <id_info>
    <org_study_id>16-306</org_study_id>
    <nct_id>NCT03204123</nct_id>
  </id_info>
  <brief_title>PSMA PET Imaging of Recurrent Prostate Cancer</brief_title>
  <official_title>PSMA PET Imaging of Recurrent Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if a new diagnostic research agent named
      68Ga-HBED-CC-PSMA can show prostate cancer on a PET/CT scan that cannot be seen on other
      standard imaging even when the PSA levels are very low.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease localization by PSMA PET/MR</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA relapse free survival in patients undergoing PSMA PET/MR guided SRT</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events assessed by common terminology criteria for adverse events (CTCAE v4.0)</measure>
    <time_frame>2 years</time_frame>
    <description>The safety and tolerability of 68Ga-HBED-iPSMA will be followed by assessing the incidence, nature and severity of toxicities by common terminology criteria for adverse events (CTCAE v4.0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Ga-HBED-iPSMA PET with CT or MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have a PET scan with Ga-HBED-iPSMA. PET may be combined with CT or MRI at the discretion of the referring clinician.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ga-HBED-iPSMA PET with MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have a PET scan with Ga-HBED-iPSMA and will be combined with MRI. If PET/MR imaging is not available, PET/CT imaging may be substituted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ga-HBED-iPSMA PET</intervention_name>
    <description>Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.</description>
    <arm_group_label>Ga-HBED-iPSMA PET with CT or MRI</arm_group_label>
    <arm_group_label>Ga-HBED-iPSMA PET with MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT</intervention_name>
    <description>CT will be acquired using a GE PET/CT scanner. Following a waiting period of 60-90 minutes, patients will be scanned from mid-skull to mid-thigh. Imaging will start with low-dose CT scan for attenuation correction.</description>
    <arm_group_label>Ga-HBED-iPSMA PET with CT or MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI will be acquired on a GE 750 3T scanner. Whole body MRI will include an axial field of view ranging from mid-skull to mid-thigh, using multichannel spine and body coils. The protocol will consist of a combination of multiplanar T1-weights and fat/water sequences and axial diffusion-weighted MRI using two b values (b=50 and b=900s/mm^2).</description>
    <arm_group_label>Ga-HBED-iPSMA PET with CT or MRI</arm_group_label>
    <arm_group_label>Ga-HBED-iPSMA PET with MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:

          -  Biopsy proven adenocarcinoma of the prostate

          -  Initially treated with definitive local therapy (surgery and radiation therapy are the
             most common treatments, but other treatments are also eligible)

          -  Biochemical recurrence defined as any of the following:

               -  PSA ≥ 0.2 ng/mL in at least two consecutive tests within 6 months of date of
                  consent for patients treated with surgery, radiation therapy, brachytherapy, or
                  cryotherapy.

               -  PSA ≥ 2 ng/ml above the most recent therapy nadir for patients who have received
                  additional treatment in the recurrent setting.

          -  Age ≥ 18 years

          -  Patient must be able to tolerate PET/CT imaging

        Exclusion Criteria:

        Cohort 1:

          -  Patient must not have claustrophobia that would preclude PET/CT imaging or other
             contraindications to CT imaging.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Osborne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph Osborne, MD, PhD</last_name>
    <phone>212-639-7788</phone>
    <email>osbornej@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Zelefsky, MD</last_name>
    <phone>212-639-6802</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Osborne, MD, PhD</last_name>
      <phone>212-639-7788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Osborne, MD, PhD</last_name>
      <phone>212-639-7788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Osborne, MD, PhD</last_name>
      <phone>212-639-7788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Osborne, MD, PhD</last_name>
      <phone>212-639-7788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Rockville Centre</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <zip>11570</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Osborne, MD, PhD</last_name>
      <phone>212-639-7788</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center at Phelps</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <zip>10591</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Osborne, MD, PhD</last_name>
      <phone>212-639-7788</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>prostatectomy</keyword>
  <keyword>biochemical recurrence</keyword>
  <keyword>Ga-HBED-iPSMA</keyword>
  <keyword>16-306</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

